AC
GBT

Ascend Capital’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Ascend Capital’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-176,515
Closed -$7.98M – 230
2018
Q2 		$7.98M Buy
176,515
+42,303
+32% +$1.93M 0.38% 90
2018
Q1 		$6.48M Buy
+134,212
New +$7.49M 0.26% 111
2017
Q4 		– Sell
-441,674
Closed -$13.7M – 264
2017
Q3 		$13.7M Buy
441,674
+82,390
+23% +$2.32M 0.52% 66
2017
Q2 		$9.82M Buy
+359,284
New +$10.7M 0.46% 76

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ascend Capital's GBT Position: Q3 2018 in Review

Ascend Capital sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2018, closing a stake of 176,515 shares — an estimated $7.98M sold.

Ascend Capital first reported a position in GBT in Q2 2017 and held it in 4 quarters. The position peaked at $13.7M in Q3 2017. 184 funds tracked by Wall St. Rank hold GBT as of Q3 2018.

  • Ascend Capital reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2018 after selling out during the quarter.
  • Ascend Capital sold 176,515 Global Blood Therapeutics, Inc. shares in Q3 2018, an estimated $7.98M.
  • Ascend Capital first reported a position in Global Blood Therapeutics, Inc. in Q2 2017 and held it in 4 quarters.
  • Ascend Capital's Global Blood Therapeutics, Inc. position peaked at $13.7M in Q3 2017.
  • 184 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2018.

Based on Ascend Capital's 13F filing for Q3 2018, filed 13 Nov 2018.